Filing Details

Accession Number:
0001104659-25-051979
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2025-05-22 16:05:12
Reporting Period:
2025-04-29
Filing Date:
2025-05-22
Accepted Time:
2025-05-22 16:05:12
Original Submission Date:
2025-05-01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1657312 Verona Pharma Plc VRNA () 4/A
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1337845 Vikas Sinha 3 More London Riverside
London X0 SE1 2RE
Yes No No No
Transaction Summary
Sold: 160,000 shares Avg. Price: $8.92 Total Value: $1,427,328.00
Number of Shares After Transactions: 74,440 shares
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2025-04-29 120,384 $1.70 194,824 No 4 M Direct
Ordinary Shares Disposition 2025-04-29 120,384 $8.92 74,440 No 4 S Direct
Ordinary Shares Acquisiton 2025-04-29 39,616 $0.50 114,056 No 4 M Direct
Ordinary Shares Disposition 2025-04-29 39,616 $8.92 74,440 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Share Options (Right to Buy) Disposition 2025-04-29 120,384 $0.00 120,384 $1.70
Ordinary Shares Share Options (Right to Buy) Disposition 2025-04-29 39,616 $0.00 39,616 $0.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2027-04-26 No 4 M Direct
160,384 2032-04-27 No 4 M Direct
Footnotes
  1. This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.
  2. Reported securities are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.
  3. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price.
  4. Consists of 74,440 Ordinary Shares represented by 9,305 ADSs.
  5. The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.
  6. The option is fully vested.